Cleave Therapeutics develops oncology pharmaceuticals designed to target neurodengeneration and pathways used by cancer cells to grow. The company is engaged in the discovery of novel, small-molecule drugs that affect protein-degradation pathways, upon which cancer cells depend for survival, enabling patients to get cured from cancer.

Patents 60show all

  • 23
    C07D - Heterocyclic compounds
  • 12
    A61K - Preparations for medical, dental, or toilet purposes
  • 9
    C12Q - Measuring or testing processes involving enzymes, nucleic acids or microorganisms
  • 9
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 2
    C07K - Peptides
  • 2
    C12Y - Enzymes
  • 1
    G16H - Healthcare informatics, i.e. information and communication technology [ict] specially adapted for the handling or processing of medical or healthcare data
  • 1
    Y02A - Technologies for adaptation to climate change

Clinical Trials 2show all

2Phase 1

Contact Information

135 Main Street Suite 1145 San Francisco, CA
San Francisco, CA 94105
United States

Overview

Total FundingEmployeesLast Funding DateStatus
$89,950,0031-102019-08-06Operating

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2019-08-06$12,000,000Series CArcus Ventures, OrbiMed, Celgene, 5AM Ventures, Astellas Venture Management, U.S. Venture Partners (USVP), OUP (Osage University Partners)
2013-04-09$10,000,000Series ANew Enterprise Associates (NEA)
2011-11-14$42,000,000Series AOrbiMed, 5AM Ventures, U.S. Venture Partners (USVP), Clarus VenturesAstellas Venture Management, OUP (Osage University Partners)
2016-08-17$25,950,003Series BNew Enterprise Associates (NEA), Nextech InvestU.S. Venture Partners (USVP), OUP (Osage University Partners), Astellas Venture Management, Clarus Ventures, 5AM Ventures, Celgene, Arcus Ventures, OrbiMed